When pharmacogenomics meets primary care reality
The Lancet Primary Care · 2026-06 · 2 (6) · 100163
DOI: 10.1016/j.lanprc.2026.100163 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Lancet Primary Care, 2026-06. Verfasst von Elisa J Houwink. Die Arbeit nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pharmacogenomic testing is often promoted as a means to improve the effectiveness and safety of antidepressant prescribing, yet its role in routine primary care remains uncertain. In The Lancet Primary Care, Jon D Emery and colleagues report the PhaRmacogEnomicS In DEpression (PRESIDE) trial, a large, pragmatic, double-blind, randomised controlled trial conducted in an Australian general practice population to evaluate whether pharmacogenomics-guided antidepressant prescribing improves outcomes for adults with moderate to severe depressive symptoms.
Zitieren
APA
Houwink, E. J. (2026). When pharmacogenomics meets primary care reality. The Lancet Primary Care, 2(6), 100163. https://doi.org/10.1016/j.lanprc.2026.100163
Vancouver
Houwink EJ. When pharmacogenomics meets primary care reality. The Lancet Primary Care. 2026;2(6):100163. doi:10.1016/j.lanprc.2026.100163
BibTeX
@article{Houwink2026,
author = {Houwink, Elisa J},
title = {When pharmacogenomics meets primary care reality},
journal = {The Lancet Primary Care},
year = {2026},
volume = {2},
number = {6},
pages = {100163},
doi = {10.1016/j.lanprc.2026.100163}
}
EUVIMED